Skip to main content
. 2015 May 12;6(24):20474–20484. doi: 10.18632/oncotarget.4105

Figure 1. Blocking Topo II expression or inhibiting Topo II activity represses AR transcriptional activity.

Figure 1

(A) LNCaP, MR49F, LNCaP95, LNCaP(AI), C4-2, 22RV1, VCaP and PC3 cells were cultured in mediums containing 5% CSS for 48h and then treated with vehicle or 1nM of R1881 for 24 hours. (B–C) Relative Topo II beta mRNA levels to GAPDH were measured by real-time PCR. LNCaP, MR49F and LNCaP95 cells were transfected with control or Topo II beta siRNA, and then treated with vehicle or 1nM of R1881 for 24 hours. AR and Topo II beta protein were detected by immunoblotting (B). Relative mRNA levels of Topo II beta, PSA and TMPRSS2 to GAPDH were measured by real-time PCR (C). (D) LNCaP, LNCaP95 and MR49F cells were cultured in RPMI1640 medium containing 5% CSS. Cells were treated with vehicle, 1nM of R1881 or 1nM of R1881 plus 5uM of ENZ for 24 hours. Cells were also co-treated with DMSO, 1uM of ICRF187 or 1uM of ICRF193 as indicated. Relative RNA levels of PSA to GAPDH were measured by real-time PCR from three independent experiments. Data represent mean ± SEM (n = 3) with P < 0.01 as ** and P < 0.001 as *** (student's t-test).